AudaxCeph Cephalogram Analysis Software
Audax d.o.o. • Radiology • 05/30/2025
Device Purpose
The AudaxCeph Cephalogram Analysis Software aims to streamline 2D dental image analysis for orthodontics and treatment planning by offering automated landmark digitization and measurement capabilities. Its scientific basis relies on validated algorithms for accurate automatic landmark detection, ensuring functionality and precision through rigorous non-clinical performance testing for clinical utility.
Summary
AudaxCeph Cephalogram Analysis Software, a product by Audax d.o.o., has received market clearance as a Class II Medical Image Management and Processing System, establishing its substantial equivalence to existing devices. Cleared on May 30, 2025, under product code QIH, this software is now available for commercial use, indicating it meets the necessary regulatory standards for medical devices. Designed for specialized dental practices, particularly in orthodontics, the software supports patient image storage, presentation, and treatment planning by enabling 2D dental image analysis, including automated landmark digitization, tracing, measurements, and superimpositions. Its safety and effectiveness were confirmed through non-clinical performance testing, encompassing comprehensive software verification, validation, and an accuracy study for automatic landmark detection, all of which demonstrated its functionality, precision, and adherence to relevant industry benchmarks.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. What specific algorithms are employed for automatic landmark detection, and how do they account for variations in anatomical structures among patients?; How does the software's accuracy and precision in landmark identification compare against manual tracing performed by experienced orthodontists, and what are the clinical implications of any observed differences?; What data privacy and security protocols are implemented to protect sensitive patient information and images managed by the AudaxCeph system?; Are there future development plans to integrate 3D imaging capabilities or allow interoperability with other dental diagnostic technologies?; What training and support are provided to clinicians to ensure proper interpretation of the software's analysis results and to mitigate potential misapplications?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Post-§524B but no clear network capability detected
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM detected in AI-generated device summary.
• SBOM not mentioned in AI-generated device summary. Under §524B (effective Oct 2023), cyber devices must provide a SBOM.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly